Phase I study of an Epstein-Barr Virus (EBV) in healthy volunteers. The vaccine works by targeting EBV glycoprotein gp350, which is found on the surface of the virus and virus-infected cells. EBV gp350 is also the primary target for neutralizing antibodies found in the blood of people naturally infected with EBV. The study is recruiting 40 healthy adults age 18-29.
https://nihrecord.nih.gov/2022/05/27/ni ... rr-vaccine
It’s been 2.5 years since the study was posted to ClinicalTrials.gov and it’s still in the recruiting status.
https://www.clinicaltrials.gov/ct2/show ... w=2&rank=1
Epstein-Barr Virus Vaccine, Phase I
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1755 Views
-
Last post by Tif
-
- 1 Replies
- 453 Views
-
Last post by Leonard
-
- 3 Replies
- 587 Views
-
Last post by Leonard
-
- 2 Replies
- 1120 Views
-
Last post by DIM
-
- 0 Replies
- 1391 Views
-
Last post by Tif
-
- 0 Replies
- 2005 Views
-
Last post by Tif
-
- 0 Replies
- 1508 Views
-
Last post by Tif
-
- 1 Replies
- 1136 Views
-
Last post by 1eye
-
- 4 Replies
- 2534 Views
-
Last post by NHE